Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620230 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects
A Phase 1 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00620230: Completed Phase 1 study, sponsored by Novartis.
NCT00620230 is a Phase 1 study that has completed, run by Novartis. The registered enrollment target is 46 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00620230, a Phase 1 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of single and multiple doses of VAK694 in healthy volunteers and otherwise healthy volunteers with a history of allergies.
Interventions
- DRUG NVP-VAK694
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
What the finished NCT00620230 record still lists
NCT00620230 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 1 intervention - of which NVP-VAK694 is the first listed.
NCT00620230 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00620230 about?
NCT00620230 is a clinical study titled "Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects". This study will evaluate the safety and tolerability of single and multiple doses of VAK694 in healthy volunteers and otherwise healthy volunteers with a history of allergies.
What is the current status of trial NCT00620230?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2007-10. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00620230?
The interventions under investigation include: NVP-VAK694 (DRUG).
Who is sponsoring clinical trial NCT00620230?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00620230's enrollment target sits among peer trials
46 1058th of 2000 higher than 935 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia